Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.